secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-034153
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody
--------------------------------------------------------------------------------

- Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).
- Positive topline Phase 1 data for RT-111 (oral anti-IL12/23 antibody): high bioavailability, well-tolerated, no serious adverse events.
- Strategic restructuring: discontinued RT-101, paused RT-105/110, reduced workforce, cost savings extend cash runway into 2025.
- Phase 2 trial of RT-102 (teriparatide for osteoporosis) to start in 2024; RaniPill HC ready for Phase 1 in H2 2024.
- Preclinical data showed transenteric delivery of GLP-1 triagonist elicits rapid weight loss; successful oral delivery of Humira via RaniPill HC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024034153/0000950170-24-034153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024034153/rani-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer